WELLCOVORIN
What it isReduced folate bypassing dihydrofolate reductase; methotrexate rescue and fluorouracil potentiation.
Why this oneIt rescues normal cells from methotrexate yet paradoxically strengthens fluorouracil's antitumor effect.
What limits it⚑ Rescue must start on time; delay makes it ineffective. It does not correct renal methotrexate retention.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Reduce methotrexate toxicity (impaired MTX elimination) | Adults | 10 mg/m² (up to 25 mg) q6h | 10 mg/m² (up to 25 mg) q6h until MTX <0.01 µM | 25 mg q6h (above this, use parenteral) |
| Folic acid antagonist / DHFR inhibitor overdose | Adults | 5–15 mg QD | 5–15 mg QD | 15 mg QD |
| FOLR1-CFTD (cerebral folate transport deficiency) | <40 kg | 1–2 mg/kg/day | up to 8.5 mg/kg/day | 8.5 mg/kg/day |
| FOLR1-CFTD | ≥40 kg | 1–2 mg/kg/day | up to 330 mg/day | 330 mg/day |
Renal Undefined
Hepatic Undefined
For MTX rescue, doses >25 mg q6h require switch to injectable leucovorin.
Pregnancy No drug-associated risk identified for intermittent use (antagonist/DHFR toxicity); concomitant chemotherapy may cause fetal harm.
Lactation No data on presence in human milk.
NO BOXED WARNINGS
Principal riskRescue must start on time or it is useless
Cost, est. cash$20–$1,500/dose or month
Generic entry1982
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
